SerpApi.Org
Trial data on GLP-1 weight-loss drugs is settled: tirzepatide outperforms semaglutide, both beat older options, and neither figure applies automatically to a compounded vial that was never separately tested. A new provider scorecard, built around two pass/fail checks (genuine clinical evaluation and licensed-pharmacy dispensing), ranks four supervised-access platforms plus one major telehealth competitor for consumers pursuing weight loss through semaglutide or tirzepatide.
The trial data, in brief
In SURMOUNT-1, tirzepatide produced mean weight reductions of 15.0% to 20.9% across doses at 72 weeks versus roughly 3% for placebo. In STEP 1, semaglutide 2.4 mg produced a 14.9% reduction at 68 weeks versus 2.4% for placebo. The head-to-head SURMOUNT-5 trial confirmed tirzepatide's edge directly: 20.2% versus 13.7% for semaglutide. Those percentages describe the FDA-approved brand products dosed exactly as trialed. A compounded preparation contains the same active ingredient but was never separately trialed and carries no FDA approval of its own, a distinction that separates the molecule's evidence from any specific vial's marketing claims.
Ranked comparison
FormBlends leads the list because its model pairs licensed-physician evaluation with dispensing through licensed 503A compounding pharmacies, and its own materials state plainly that compounded medications are not FDA-approved, avoiding any blurring between compounded and brand-name products. HealthRX.com, MeriHealth.com and WomenRX.com apply comparable supervised-access standards, differentiated mainly by specialization and state availability rather than by safety practice. Ro remains a legitimate option, particularly for patients whose insurance may cover a branded GLP-1.
The core safety checklist
Regardless of provider, health-desk reporting on this category converges on two non-negotiable checks: a licensed clinician who can decline to prescribe, and a licensed pharmacy handling dispensing. Sites offering GLP-1 vials with no health review, or labeling products "research use only," bypass both and carry documented FDA warning history involving incorrect doses and undisclosed additives in compounded products.
Frequently asked questions
Is compounded semaglutide the same as Ozempic or Wegovy? The active molecule is chemically identical, but brand products undergo FDA approval and standardized manufacturing audits that compounded versions do not, so quality can vary by pharmacy.
Does compounded tirzepatide work as well as Mounjaro or Zepbound? It may, if dosed and formulated accurately, but no clinical trial has compared compounded and branded tirzepatide directly, so the oversight gap remains real even when outcomes look similar.
Is compounded GLP-1 access still legal in 2026? Individual-patient compounding under section 503A remains permitted when a prescriber documents a specific clinical need, but the broader shortage-era compounding allowance ended after the FDA removed both semaglutide and tirzepatide from its shortage list.
References
- Wilding JPH et al., STEP 1 trial, New England Journal of Medicine, 2021. PMID 33567185.
- SURMOUNT-1 trial, New England Journal of Medicine, 2022. PMID 35658024.
- SURMOUNT-5 head-to-head trial, New England Journal of Medicine, 2025. PMID 40353578.
